DIRS.INFO The most relevant business & tech news

☆ 15 best skin care products for rosacea and redness
▼ + stars: | 2022-10-17 | by ( Mili Godio | Mili Godio Is An Associate Reporter For Select On Nbc News. | ) www.nbcnews.com time to read: +20 min

SKIP AHEAD Best products for rosacea | How to best manage rosacea | What type of products should you avoid with rosacea? The best products for rosacea in 2022Our expertssaid that a skin routine with gentle, non-abrasive products is best for people with rosacea. Cetaphil’s Gentle Skin Cleanser is recommended by dermatologists thanks to its gentle, non-foaming formula that helps hydrate and soothe rosacea-prone skin. Clinique’s Redness Solutions skin care line offers everything from cleansers to sunscreens that can be beneficial for those with redness and rosacea. Like Avene, La Roche-Posay is a French brand that makes gentle products for sensitive skin — our experts recommended this brand for both rosacea and acne-prone skin.

☆ Texas-based oil giant accused of failing to help its Russian workers avoid being conscripted by Putin, report says
▼ + stars: | 2022-10-15 | by ( Ryan Hogg | ) www.businessinsider.com time to read: +3 min

Schlumberger is passing draft notices on to some of its 9,000 Russian employees, Reuters reported. Some workers have begun receiving draft notices ordering them to join the Russian army, according to a report by the news agency. The BHRRC told Reuters that Roche and Novo Nordisk, two other non-Russian companies, had requested military exemptions for their employees. "The local leadership team is managing an incredibly complex and difficult situation," a Schlumberger spokesperson told Reuters in an emailed statement. The US-based spokesperson added that managers were obliged "to comply with local laws and regulations, especially when failure to do so could create additional risk for our local employees."

☆ EXCLUSIVE Schlumberger faces employee backlash in Russia over cooperation on draft
▼ + stars: | 2022-10-14 | by ( Liz Hampton | ) www.reuters.com time to read: +5 min

Human rights groups are watching how the company responds to the concerns. Schlumberger suspended new investments and technology deployment in Russia, but unlike some of its peers and customers, decided to remain. Schlumberger leaves decision-making on Russia employment policies to local managers, the U.S.-based spokesperson said. The Business & Human Rights Resource Centre requested information from Schlumberger and other non-Russian companies with operations in the country on their handling of the mobilization. Schlumberger rivals Baker Hughes (BKR.O) and Halliburton (HAL.N) are selling or have sold their oilfield services units in Russia.

☆ This income-building fund stayed resilient this year by focusing on the 'power of dividends'
▼ + stars: | 2022-10-14 | by ( Sarah Min | ) www.cnbc.com time to read: +4 min

Ben Kirby says his fund has stayed resilient this year by doing what it's always done: remembering the "power of dividends." "People forget about the power of dividends, and they forget how important it is to get that current income," Kirby said. Today, TIBIX has a roughly 16% allocation to fixed income, compared with "closer to 10%" over the past decade, according to the fund manager. And you know, I can see us going back above our long term average of 20%," Kirby said. Still, Kirby said he's taking his time allocating more to fixed income as he finds many equities very attractive.

☆ Biogen's Alzheimer's drug could be more competitive than peers, Stifel says in upgrade to buy
▼ + stars: | 2022-10-13 | by ( Sarah Min | ) www.cnbc.com time to read: +1 min

Biogen 's new Alzheimer's treatment could lead to even stronger gains for the biotech company going forward, according to Stifel. Analyst Paul Matteis upgraded shares of the biotech company to buy from hold, saying that upcoming data for Alzheimer treatments from competitors Roche and Eli Lilly could show that clinical results for Biogen's product, lecanemab, could be more competitive than feared. "Gantenerumab and donanemab readouts are overhangs for Biogen, but there's reason to think that in most scenarios, lecanemab will have a competitive clinical profile," he added. Shares of Biogen outperformed this year, up 5.7%, as investors pivoted into health care companies for their defensive attributes. Still, the analyst is concerned about challenges for the biotech company, including uncertainty around the company's future CEO.

☆ Alzheimer’s Blockbuster Might Spur Investor Bonanza, Higher Medicare Costs
▼ + stars: | 2022-09-28 | by ( David Wainer | ) www.wsj.com time to read: 1 min

The Biogen drug is likely to get accelerated approval from the FDA in January due to the positive data. The Alzheimer’s drug data released Tuesday night aren’t only going to be transformative for Biogen which has been struggling to get love from investors after its botched launch of Aduhelm. The results are also breathing new life into a class of anti-amyloid drugs that had been partially written off, increasing investor confidence that drugs from Eli Lilly and Roche Holding also deliver positive results.

☆ The success of Biogen's new Alzheimer's drug could be the start of a redemption arc for the biotech — and boost rivals racing to develop similar treatments
▼ + stars: | 2022-09-28 | by ( Yeji Jesse Lee | ) www.businessinsider.com time to read: +3 min

Biotech companies Biogen and Eisai just released data on their new Alzheimer's drug. Initial results of a highly anticipated test of an Alzheimer's drug, called lecanemab, were released on Tuesday evening by biotech firms Biogen and Eisai. "While the market has been skeptical of lecanemab's prospects, the trial appears to be a resounding success," Cowen analysts said. An earlier Alzheimer's drug developed by Biogen and Eisai, Aduhelm, also acts on beta-amyloid. Mizhuo analyst Graig Suvannavejh, said that the lecanemab results are "a key potential positive catalyst for companies" working to develop Alzheimer's treatments.

☆ Analysis: Alzheimer's drug trial breakthrough boost for Roche, Eli Lilly
▼ + stars: | 2022-09-28 | by ( Natalie Grover | ) www.reuters.com time to read: +5 min

Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. Nearly all Alzheimer's drugs, including those targeting amyloid, have stumbled in trials. Late-stage data on gantenerumab is expected by the fourth quarter, Roche said in a statement, saying it was encouraged by the lecanemab data. Results of a key late-stage trial testing the drug are anticipated by mid-2023. AMYLOID HYPOTHESISSome researchers, including Frederiksen, are cautiously optimistic about the impact the Biogen, Eisai data has on the likelihood of success for the other two drugs in development.

☆ Biogen and Eisai's latest clinical trial just crossed the finish line. Here's why analysts say the results could disrupt the future of Alzheimer's care.
▼ + stars: | 2022-09-28 | by ( Yeji Jesse Lee | ) www.businessinsider.com time to read: +7 min

It's a complicated, debilitating illness and drug companies have struggled for years to come up with viable treatments. On Tuesday September 27, Biogen and Eisai announced that lecanemab slowed the rate of cognitive decline in Alzheimer's patients by 27%. Analysts say that this positive result could lead to it becoming a blockbuster drug for the companies. Other big drug companies such as Roche Holdings and Eli Lilly are pursuing similar treatments, with results expected to come later this year and early next year, respectively. "I think people's confidence in the amyloid hypothesis would go down even further, but ultimately people would wait to see what those other data events show," he said.

☆ Here's why Biogen's promising Alzheimer's drug data is also good news for Eli Lilly
▼ + stars: | 2022-09-28 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +8 min

The move helped Eli Lilly notch a fresh 52-week high Wednesday, the only stock in the S & P 500 to do so. Bottom line Biogen's topline data appears to be encouraging, suggesting the Alzheimer's drug helped slowed cognitive decline. Plus, we think Eli Lilly has more going for it overall than Biogen, making it a more attractive investment. Drug background Like Biogen's Alzheimer's drug lecanemab, Lilly's donanemab is an antibody that tries to reduce buildup on the brain of the amyloid beta protein . The Eli Lilly logo is shown on one of the company's offices in San Diego, California, September 17, 2020.

☆ Biogen soars 43% after its Alzheimer's drug helps slow down cognitive decline in late-stage study
▼ + stars: | 2022-09-28 | by ( Matthew Fox | ) www.businessinsider.com time to read: +3 min

Biogen soared 43% on Wednesday after the company's Alzheimer's drug showed solid results in slowing the cognitive decline of patients. The drug, lecanemab, slowed cognitive decline by 27% after 18 months in a phase three clinical trial. Specifically, the drug helped reduce the pace of cognitive decline in people with early Alzheimer's by 27% over 18 months, compared to a placebo. The drug is separate from Biogen's aduhelm Alzheimer's drug, which was approved by the FDA last year in what was seen as a controversial decision. Biogen's positive Alzheimer's drug results is moving a handful of stocks that are focused on developing therapies in the space.

The trial results released on late Tuesday could mark a rare victory in the search for a treatment for the memory-robbing disease after years of clinical failures. Biogen's stock surged 46.6% to $290.99 in premarket trading, putting it on track to add over $13.5 billion in market capitalization. BMO analyst Evan Seigerman called the data an "unequivocal win" for Biogen and Alzheimer's patients. The latest trial boost for Biogen and Eisai's lecanemab has raised hope for success in trials testing Roche's gantenerumab and Lilly's donanemab. Shares of smaller Alzheimer's drug developers also rose in premarket U.S. trading.

The Japanese drugmaker Eisai said Tuesday its experimental drug for Alzheimer’s disease helped slow cognitive decline in patients in the early stages of the illness. The company said that in a phase 3 clinical trial, the drug, called lecanemab, slowed cognitive decline by 27% after 18 months. The results may offer renewed hope to Alzheimer’s patients after the U.S. drugmaker Biogen’s botched rollout of its drug, Aduhelm, last year. Biogen partnered with Eisai in the commercialization of the new drug, although Eisai led its development and the phase 3 trial. Two similar drugs — from Roche and Eli Lilly — are expected to release late-stage clinical trial results over the next few months.

Globally, the figure could reach 139 million by 2050 without an effective treatment, Alzheimer's Disease International said. Aduhelm was the first new Alzheimer's drug approved in 20 years after a long list of high-profile failures for the industry. read morePatient advocacy groups hailed the news of positive lecanemab trial results. Micro hemorrhages in the brain occurred at a rate of 17% in the lecanemab group, and 8.7% in the placebo group. Aduhelm's approval was a rare bright spot for Alzheimer's patients, but critics have called for more evidence that amyloid-targeting drugs are worth the cost.

Shares of Biogen and Eisai were halted, but shares of Eli Lilly & Co , which is also developing an Alzheimer's drug, were up 6.7% in after hours trade. Aduhelm was the first new Alzheimer's drug approved in 20 years after a long list of high-profile failures for the industry. Symptomatic brain swelling was seen in 2.8% of those in the lecanemab group and none of the placebo group, they said. Aduhelm's approval was a rare bright spot for Alzheimer's patients, but critics have called for more evidence that amyloid-targeting drugs are worth the cost. Other plaque-targeting antibodies in late-stage development for Alzheimer's patients include Roche Holding AG's (ROG.S) gantenerumab and Eli Lilly's donanemab.

☆ GSK picks Burberry's Brown as CFO
▼ + stars: | 2022-09-26 | by ( ) www.reuters.com time to read: +2 min

Register now for FREE unlimited access to Reuters.com RegisterGSK (GlaxoSmithKline) logo is seen in this illustration, August 10, 2022. REUTERS/Dado Ruvic/Illustration/SummarySummary Companies Brown to join GSK in April, start as CFO in MayCFO Iain Mackay to retireSept 26 (Reuters) - GSK (GSK.L) named luxury fashion brand Burberry's (BRBY.L) Julie Brown as its new chief financial officer on Monday to succeed Iain Mackay, at a time when the British drugmaker is sharpening focus on its core business. The change comes after GSK spun off its large consumer business, Haleon (HLN.L), to focus on prescription drugs and vaccines. Burberry had said on Friday that Brown would step down as its CFO and chief operating officer in April to take up a role outside the luxury industry. Register now for FREE unlimited access to Reuters.com RegisterReporting by Amna Karimi and Pushkala Aripaka in Bengaluru; Editing by Subhranshu Sahu and Louise HeavensOur Standards: The Thomson Reuters Trust Principles.

Mackay, 60, will be retiring next year after serving as GSK's finance chief for nearly four years, following an eight-year stint as group finance director at the bank HSBC. Register now for FREE unlimited access to Reuters.com RegisterBrown, also 60, will join GSK in April and take up the job in May. She also served in several finance roles at AstraZeneca (AZN.L), which last year also appointed a female CFO, Aradhana Sarin. With Emma Walmsley as GSK's chief executive officer, Brown's appointment also creates a rare, all-female top management at a blue-chip (.FTSE) British company and a global pharma major. Brown will receive an annual base salary of more than 900,000 pounds at GSK, the company said.

Register now for FREE unlimited access to Reuters.com RegisterGSK (GlaxoSmithKline) logo is seen in this illustration, August 10, 2022. REUTERS/Dado Ruvic/Illustration/SummarySummary Companies Brown to join GSK in AprilIain Mackay to retire in MaySept 26 (Reuters) - Britain's GSK (GSK.L) has appointed its first female chief financial officer, Julie Brown, to succeed Iain Mackay, as the drugmaker focuses on its core pharmaceuticals business. With Emma Walmsley as GSK's chief executive, Brown's appointment also creates a rare, all-female top management at a blue-chip (.FTSE) British company and a global pharma major. Mackay, 60, will retire next year after almost four years as GSK's finance chief, before which he completed an eight-year stint as group finance director at HSBC. She also served in several finance roles at AstraZeneca (AZN.L), which last year appointed a female CFO, Aradhana Sarin.

☆ Embattled CEO Werner Baumann enters his final chapter at Bayer, aiming to turn the German pharma giant into a cancer powerhouse
▼ + stars: | 2022-09-22 | by ( Andrew Dunn | ) www.businessinsider.com time to read: +6 min

With a successor search underway, Werner Baumann is entering his last chapter as Bayer's CEO. Baumann told Insider he's more excited today about Bayer's future than several years ago. The exec wants Bayer to become a top 10 cancer player by 2030, and recently opened a Cambridge lab. CAMBRIDGE, Massachusetts — Within his first month as CEO of the German giant Bayer, Werner Baumann took a big, legacy-making swing. Baumann says Bayer's future is in oncologyWerner Baumann, right, CEO of Bayer, and Werner Wenning, chairman of the Supervisory Board of Bayer.

Register now for FREE unlimited access to Reuters.com RegisterSwiss drugmaker Novartis' logo is seen at the company's plant in the northern Swiss town of Stein, Switzerland October 23, 2017. Register now for FREE unlimited access to Reuters.com RegisterIt ranked 10th in the U.S. market last year, the company added. Novartis also said it would focus in future on five areas for investment: cardiovascular, immunology, neuroscience, solid tumors and hematology medicine. The company last month said it planned to spin off Sandoz to sharpen its focus on its patented prescription medicines. Register now for FREE unlimited access to Reuters.com RegisterEditing by Mark Potter and Jason NeelyOur Standards: The Thomson Reuters Trust Principles.

☆ Biogen's latest clinical trial is inching towards the finish line. Here's why analysts say the results could disrupt the future of Alzheimer's care.
▼ + stars: | 2022-09-19 | by ( Yeji Jesse Lee | ) www.businessinsider.com time to read: +7 min

It's a complicated, debilitating illness and drug companies have struggled for years to come up with viable treatments. Other big drug companies such as Roche Holdings and Eli Lilly are pursuing similar treatments, with results expected to come later this year and early next year, respectively. "I think people's confidence in the amyloid hypothesis would go down even further, but ultimately people would wait to see what those other data events show," he said. Negative results might give a boost to companies that are exploring alternate ways to treat Alzheimer's disease. And though Biogen's drug is furthest along in development, it's far from being the only treatment being tested for Alzheimer's.

☆ Why a top Roche scientist is leaving after 25 years to join a rising biotech startup using fungi to make new drugs
▼ + stars: | 2022-09-16 | by ( Andrew Dunn | ) www.businessinsider.com time to read: +5 min

After 25 years at the pharma giant Roche, the drug hunter Martin Stahl is leaving to join a biotech. CAMBRIDGE, Massachusetts — A longtime drug-hunting veteran is leaving one of the largest drugmakers to lead the science division at the biotech startup LifeMine Therapeutics, Insider has learned. FogPharmaThe big draw for Stahl was LifeMine's approach to discovering drugs. With its genetic-database approach, LifeMine hopes to greatly speed up how long it takes to develop fungi-derived drugs. Stahl said LifeMine's approach leaned on nature, rather than medicinal chemists, to design the drugs.

☆ WHO 'strongly advises against' use of two COVID treatments
▼ + stars: | 2022-09-15 | by ( Natalie Grover | ) www.reuters.com time to read: +3 min

A woman holds a small bottle labelled with a "Coronavirus COVID-19 Vaccine" sticker and a medical syringe in this illustration taken October 30, 2020. The virus has since evolved, and mounting evidence from lab tests suggests the two therapies - sotrovimab as well as casirivimab-imdevimab - have limited clinical activity against the latest iterations of the virus. Another COVID therapy that emerged early in pandemic was Gilead's (GILD.O) antiviral remdesivir. The WHO expanded its conditional recommendation for the drug, advising that it can be used in patients with severe COVID as well as non-severe COVID patients at the highest risk of hospitalization. There are a handful of existing COVID therapeutics that remain useful in the fight against the virus, and others in development that are expected to also benefit patients.

☆ See the 20-slide presentation this biotech startup used to raise $75 million for a way to treat blindness with CRISPR
▼ + stars: | 2022-09-14 | by ( Andrew Dunn | ) www.businessinsider.com time to read: +2 min

About a year ago, the startup secured an exclusive deal with CRISPR gene-editing leader Intellia. SparingVision, a Paris-based startup, just raised $75 million to advance a suite of gene-therapy and gene-editing programs to treat eye diseases. The company plans to use the funds to enter the clinic with its first gene-therapy program. The cash will also help advance SPVN50, SparingVision's first gene-editing program. The program came out of a research collaboration SparingVision struck with Intellia Therapeutics, a CRISPR gene-editing leader, last year.

As yet another Alzheimer's drug targeting plaque buildup in the brain fails to improve cognition in patients, leading scientists said a significant shift is underway in the search for effective treatments for the disease. By 2050, that number is projected to rise to nearly 13 million, according to an estimate from the Alzheimer’s Association. Alzheimer’s disease is often referred to as “Type 3 diabetes,” a brain-specific form of diabetes that is the result of the brain’s neurons lacking glucose, said John Didsbury, the CEO of T3D Therapeutics. Data from the longest-ever phase 3 trial of exercise on cognition released at the conference on Tuesday found that exercise may stall cognitive decline in Alzheimer’s patients. He said it’s only a matter of time before we see more research discoveries that show potential for slowing Alzheimer’s disease, possibly within the next year or two.

Search resuls for: "Roche"

25 mentions found